Medicines to Treat Pituitary Tumors

Many medicines can be used to treat pituitary tumors. For some pituitary tumors, medicine might be the only treatment needed. For other tumors, medicines might not be used unless other treatments such as surgery or radiation therapy aren’t effective.

Drugs for lactotroph adenomas (prolactinomas)

Prolactinomas make too much prolactin, which might cause symptoms such as lowered sexual interest, erectile dysfunction in men, or excess milk production or infertility in younger women. These tumors might also grow large enough to press on nearby nerves, causing symptoms such as headaches or changes in vision.

Dopamine agonists

These medicines can usually stop prolactinomas from making too much prolactin and can shrink these tumors. Dopamine agonists work so well that surgery usually isn’t needed. Even if the tumor doesn’t shrink, these drugs often can keep prolactinomas from growing larger. It's rare that prolactinomas become resistant to these drugs.

  • Cabergoline is the drug most commonly used.
  • Bromocriptine is another option.

Both drugs work well, but cabergoline seems to work better, and it can be taken once or twice a week, whereas bromocriptine typically needs to be taken twice a day.

Possible side effects of dopamine agonists include drowsiness, dizziness, nausea, vomiting, diarrhea or constipation, headaches, confusion, depression, and problems with impulse control. For women whose high prolactin levels had been causing infertility, these drugs might restore fertility. Cabergoline might cause fewer side effects than bromocriptine.

Drugs for somatotroph adenomas (growth hormone-secreting tumors)

These tumors make too much growth hormone (GH), also known as somatotropin, which can lead to acromegaly in adults and gigantism in children. To learn more, see Signs and Symptoms of Pituitary Tumors.

Surgery is often the first treatment for these tumors, but medicines might be helpful if the tumor can’t be removed completely, or if a person can’t have surgery for some reason.

Somatostatin analogs are lab-made forms of the hormone somatostatin. They block the production of GH.

Examples of somatostatin analogs include:

  • Octreotide (Sandostatin, Mycapssa)
  • Lanreotide (Somatuline Depot)
  • Pasireotide (Signifor LAR)

All 3 of these drugs are available in long-acting forms, which can be injected under the skin every 4 to 6 weeks. Octreotide and lanreotide are used more often. Pasireotide is more likely to raise blood glucose (sugar) levels, so it usually isn't used unless the other drugs don’t work.

Octreotide is also available as a capsule that can be taken by mouth, typically twice a day. This might be an option for people whose tumors have responded to long-acting octreotide or lanreotide injections.

Doctors measure how well these drugs are working by checking your blood GH and IGF-1 levels. These drugs can return these levels to normal in about half of people, although tumors tend to shrink very slowly.

Side effects of somatostatin analogs can include a slowed heart rate, nausea, vomiting, diarrhea, gas, stomach pain, dizziness, headache, and pain at the site of injection. Many of these side effects improve or go away with time. They can also cause gallstones, and pasireotide might cause diabetes or worsen it if a person already has it.

Paltusotine (Palsonify) works in much the same way as somatostatin analogs and helps stop adenoma cells from making too much GH.

This drug can be used to treat adults whose tumors can’t be removed completely, or who can’t have surgery for some reason.

Paltusotine is taken by mouth as a pill, typically once a day. Doctors can measure how well this drug is working by checking blood GH and IGF-1 levels.

Side effects of paltusotine can include diarrhea, nausea, vomiting, loss of appetite, and belly pain. Less common but more serious side effects can include gallstones, changes in blood sugar levels, changes in heart rate, low thyroid hormone levels, and fatty stools.

Pegvisomant (Somavert) works by blocking the action of growth hormone (GH) on other cells. It's very effective in lowering blood IGF-1 levels, but it doesn’t block GH secretion by the pituitary gland. It also doesn't shrink pituitary tumors, so regular MRIs are needed to make sure the tumor isn't growing.

This drug is injected under the skin, typically once a day, but over time it might be given less often, such as every other day. It can be used alone, along with a somatostatin analog, or along with cabergoline (see below).

Pegvisomant tends to have few side effects, but it can lower blood sugar levels and cause mild liver damage in some people.

Dopamine agonists such as cabergoline or bromocriptine, described in more detail above in “Drugs for lactotroph adenomas (prolactinomas),” can reduce GH levels and help with mild acromegaly in some people, although they don’t seem to be as effective as somatostatin analogs.

Higher doses are needed for these tumors than for prolactinomas, and some people have trouble with the side effects they can cause. An advantage of these drugs is that they can be taken as a pill.

Drugs for corticotroph adenomas (ACTH-secreting tumors)

These pituitary tumors cause the adrenal glands to make excess steroid hormones such as cortisol, which can lead to Cushing disease.

Surgery is typically the preferred treatment for these tumors, if possible. Medicines can be used to treat Cushing disease if surgery and radiation therapy don’t work or are not good options. Medicines can also sometimes be used to control cortisol levels while waiting for radiation to work, which can often take many months.

Many types of medicines can be used, but they don’t always work as well for ACTH-secreting tumors as they do for some other types of pituitary tumors.

Pasireotide (Signifor) is a somatostatin analog that can help some people who have Cushing disease when surgery isn’t an option or hasn’t worked. Along with side effects such as nausea, vomiting, and diarrhea, this drug can cause high blood sugar levels and gallstones.

Cabergoline is a dopamine agonist that also can help some people with Cushing disease. For more about this drug, see “Drugs for lactotroph adenomas (prolactinomas),” above.

Steroidogenesis inhibitors can be used to keep the adrenal gland from making cortisol, but they don’t affect the pituitary tumor itself. These drugs include osilodrostat (Isturisa), ketoconazole, levoketoconazole, etomidate, metyrapone, and mitotane. These drugs can sometimes lower cortisol levels too much, which can lead to side effects such as feeling very tired, nausea, low blood pressure, dizziness, and loss of appetite.

Mifepristone is a cortisol receptor blocker. It limits the effects of cortisol on other tissues in the body. This drug can help treat high blood sugar levels in people with Cushing disease, but it doesn’t affect the pituitary tumor itself. It can have serious side effects and requires close monitoring.

Drugs for thyrotroph adenomas (thyrotropin [TSH]-secreting tumors)

The main treatment for these rare tumors is typically surgery to try to remove the tumor completely. But it’s important to restore thyroid hormone levels to normal before surgery. This is usually done by giving a somatostatin analog such as octreotide (see "Drugs for somatotroph adenomas," above) before the surgery. This might also help shrink the tumor and make the surgery easier.

If the tumor isn’t removed completely by surgery, medicines that might be used include:

  • A somatostatin analog such as octreotide or lanreotide
  • A dopamine agonist such as cabergoline or bromocriptine

For more details on dopamine agonists, see “Drugs for lactotroph adenomas (prolactinomas),” above.

Drugs for non-functional pituitary tumors

These tumors don't make excess hormones. Surgery is typically the first treatment for these tumors, which might be followed by radiation if the tumor can't be removed completely or if it comes back after surgery.

If these treatments aren’t effective, drugs such as dopamine agonists or somatostatin analogs (discussed above) might be helpful for some people, although studies of these medicines have had mixed results.

Drugs for aggressive pituitary tumors and pituitary carcinomas

These types of tumors are uncommon, but they tend to grow quickly. They might invade nearby structures or spread to other parts of the body.

For functioning tumors (those making excess hormones), many of the same drugs described above can be used, depending on which hormone the tumor makes, although higher doses and/or combinations of drugs might be needed.

Because these tumors tend to grow quickly, chemotherapy drugs, which attack rapidly growing cells, can sometimes be helpful. Temozolomide is the chemo drug used most often, but others might be tried if it isn’t working.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

Auriemma RS, Grasso LF, Pivonello R, Colao A. The safety of treatments for prolactinomas. Expert Opin Drug Saf. 2016;15(4):503-512.

Melmed S, Katznelson L. Treatment of acromegaly. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/treatment-of-acromegaly on March 3, 2026.

Molitch ME. Diagnosis and treatment of pituitary adenomas: A review. JAMA. 2017;317(5):516-524.

National Cancer Institute. Pituitary Tumors Treatment (PDQ®)–Health Professional Version. 2024. Accessed at https://www.cancer.gov/types/pituitary/hp/pituitary-treatment-pdq on March 4, 2026.

Nieman LK. Medical therapy of hypercortisolism (Cushing syndrome). UpToDate. 2026. Accessed at https://www.uptodate.com/contents/medical-therapy-of-hypercortisolism-Cushing-syndrome on March 3, 2026.

Snyder PJ. Management of hyperprolactinemia. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/management-of-hyperprolactinemia on March 3, 2026.

Snyder PJ. Treatment of gonadotroph and other clinically nonfunctioning pituitary adenomas. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/treatment-of-gonadotroph-and-other-clinically-nonfunctioning-pituitary-adenomas on March 4, 2026.

Weiss RE, Refetoff S. TSH-secreting pituitary adenomas. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/tsh-secreting-pituitary-adenomas on March 3, 2026.

Last Revised: May 8, 2026

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.